On Oct 23, major Wall Street analysts update their ratings for $Quest Diagnostics (DGX.US)$, with price targets ranging from $165 to $185.
BofA Securities analyst Michael Ryskin maintains with a buy rating, and sets the target price at $179.
Citi analyst Patrick B Donnelly maintains with a buy rating, and adjusts the target price from $165 to $185.
Barclays analyst Stephanie Davis maintains with a hold rating, and adjusts the target price from $154 to $168.
Evercore analyst Elizabeth Anderson CFA maintains with a hold rating, and maintains the target price at $165.
Mizuho Securities analyst Ann Hynes maintains with a buy rating.
Furthermore, according to the comprehensive report, the opinions of $Quest Diagnostics (DGX.US)$'s main analysts recently are as follows:
The integration of LifeLabs and consistent elevated utilization trends are the main factors behind the updated guidance for Quest Diagnostics. The company's defensive characteristics, especially during an election cycle, and more secure estimates for future years remain positive aspects highlighted by analysts.
Quest Diagnostics delivered a strong performance in the third quarter, exceeding expectations. The company maintained its earnings forecast even in the face of challenges posed by hurricanes. Additionally, preliminary insights regarding the fiscal year 2025 appear promising.
The laboratory sector is viewed favorably for the year 2025, with the belief that it is unnecessary to shy away from an investment due to cost considerations when compared to alternatives. Quest Diagnostics is seen as having a series of drivers that will contribute to expedited growth in 2025. Notably, the company's growth is expected to continue due to the completion of eight acquisitions in the preceding year.
Here are the latest investment ratings and price targets for $Quest Diagnostics (DGX.US)$ from 7 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間10月23日，多家華爾街大行更新了$奎斯特診療 (DGX.US)$的評級，目標價介於165美元至185美元。
美銀證券分析師Michael Ryskin維持買入評級，目標價179美元。
花旗分析師Patrick B Donnelly維持買入評級，並將目標價從165美元上調至185美元。
巴克萊銀行分析師Stephanie Davis維持持有評級，並將目標價從154美元上調至168美元。
Evercore分析師Elizabeth Anderson CFA維持持有評級，維持目標價165美元。
瑞穗證券分析師Ann Hynes維持買入評級。
此外，綜合報道，$奎斯特診療 (DGX.US)$近期主要分析師觀點如下：
LifeLabs的整合和持續增長的利用率趨勢是更新奎斯特診療指引背後的主要因素。公司的防禦特徵，尤其是在選舉週期期間，以及未來幾年更可靠的估計仍然是分析師強調的積極因素。
奎斯特診療在第三季度表現強勁，超過預期。即使面臨颶風帶來的挑戰，該公司仍然保持其盈利預測。此外，關於2025財政年度的初步見解似乎是令人鼓舞的。
實驗室板塊在2025年被看好，相信與其他選擇相比，由於成本考慮，投資無需迴避。奎斯特診療被視爲擁有一系列能促進2025年加速增長的推動因素。值得注意的是，由於前一年完成了八筆收購，該公司的增長預計將繼續。
以下爲今日7位分析師對$奎斯特診療 (DGX.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
